RxDoctor Payments Data

Eugene Go, MD

Pulmonary Disease · Orlando, FLNPI 1730166125

Payments from drug & device makers

$88,505in general payments, 2019–2025

Across 972 payments — averaging $91.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$40K
  • Teva Pharmaceuticals USA, Inc.$35K
  • GSK$3K
  • AstraZeneca$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Philips North America LLC$1K
  • plus $7K from 39 others

What the payments were for

  • Food & beverage$14,37498%
  • Education$2202%
  • Gifts$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,505 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$376,491
Medicare patients
1,467
Services billed
3,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate77$944,749
Trelegy ElliptaFluticasone/Umeclidin/Vilanter525$708,189
Fasenra PenBenralizumab30$174,473
Breztri AerosphereBudesonide/Glycopyr/Formoterol114$151,974
Spiriva RespimatTiotropium Bromide120$142,943
Dupixent PenDupilumab37$133,329
Stiolto RespimatTiotropium Br/Olodaterol Hcl91$97,105
Breo ElliptaFluticasone/Vilanterol93$87,560
SymbicortBudesonide/Formoterol Fumarate130$62,770
Dupixent SyringeDupilumab14$50,989
Ambrisentan14$50,987
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$41,200
Albuterol Sulfate HfaAlbuterol Sulfate736$32,987
Arnuity ElliptaFluticasone Furoate64$25,327
Combivent RespimatIpratropium/Albuterol Sulfate21$23,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$790$1,208,400309 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$2,634$885,457749 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,766$214,744244 claims
MerckDulera$148$7,43111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →